Abstract:Transplant oncology is an expanding area of cancer therapy that specifically emphasizes the use of liver transplantation (LT) as the preferred treatment for patients with manageable, but unresectable, tumors. The management and optimization of overall survival strategies, accompanied by an arguably decent quality of life, have been at the forefront of liver oncology treatment, as a plurality of all primary liver cancers are identified as either hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), which are classified as highly aggressive malignancies and frequently remain asymptomatic until they progress to advanced stages, rendering curative procedures, such as resection, impractical. This has led to an increase in utilization of neoadjuvant interventions conducted prior to surgery, which has yielded favorable outcomes. Though this treatment modality has prompted further investigations into the efficacy of immune checkpoint inhibitors (ICPIs) as standalone treatments and in combination with locoregional treatments (LRTs) to bridge more patients into curative eligibility. This multidisciplinary methodology and treatment planning has seen multiple successful trials of immunotherapy regimes and combinate treatments, setting the groundwork for increasing eligibility through downstaging and "bridging" previously ineligible patients within stringent LT criteria. Surveillance after LT is a crucial component of transplant oncology. The emergence of circulating tumor DNA (ctDNA) has provided a novel approach to identifying the recurrence of cancer in its early stages. Recent research has focused on liquid biopsy, a technique that effectively identifies the dynamics of cancer. This is another innovation to demonstrate the rate at which transplant oncology is rapidly advancing, making the focus of care feel disorienting. Modalities of care are constantly evolving, but when a field is changing as rapidly as this one, it is imperative to reorient to the data and the needs of the patients. In this commentary, we reflect on the update's utilization of ICPIs in neoadjuvant settings as well as the updates on the utilization of liquid biopsy in post-LT follow-up surveillance.

Transplant oncology and stratified management of hepatocellular carcinoma

Downstaging treatment for patients with hepatocelluar carcinoma before transplantation

Relationship Between Clinicopathologic Features and Neoplasm Recurrence,prognosis in Hepatocellular Carcinoma after Liver Transplantation

Research progress in downstaging treatment of hepatocellular carcinoma before liver transplantation

Recent Advances in Liver Transplantation for Hepatocellular Carcinoma

Prevention and Treatment Strategies of Postoperative Tumor Recurrence after Liver Transplantation for Hepatocellular Carcinoma

Liver transplantation for hepatocellular carcinoma: Current status in Hong Kong, China

Perioperative diagnosis and treatment strategies of liver transplantation for liver cancer in precision medicine era

Research progress of neoadjuvant therapy for hepatocellular carcinoma

Prevention and Management of Recurrence and Metastasis of Hepatocellular Carcinoma after Liver Transplantation

Progress and hot spots of comprehensive treatment for primary liver cancer

Progress in Surgical Procedures of Hepatocellular Carcinoma

Transplant Oncology: An Emerging Discipline of Cancer Treatment

Role of Liver Transplantation in Treatment of Liver Malignancy

Therapeutic Management of Recurrent Hepatocellular Carcinoma after Liver Transplantation

Clinical Analysis of 36 Cases of Primary Hepatocellular Carcinoma with Liver Transplantation

Liver Transplantation for Liver Cancer in the Era of Immunotherapy

Focal Update on Immunotherapy and Liver Transplantation in the Era of Transplant Oncology

Progress in hepatectomy for hepatocellular carcinoma and peri-operation management

[Liver Transplantation for Treating Hepatocellular Carcinoma].

Application of targeted therapy and immunotherapy in adjuvant and neoadjuvant therapy of hepatocellular carcinoma